Trial Profile
A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs SRF 231 (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Surface Oncology
- 19 Oct 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Interim results (as of 11 Jan 2020; n=46) assessing safety of SRF231 in patients with advanced solid and hematologic malignancies, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 14 May 2020 According to a Surface Oncology media release, the company expects to present data from this trial at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31.